Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
KRAS G12C Mutant Solid Tumors · Carcinoma, Non-Small-Cell Lung · Carcinoma, Colorectal · Cancer of Lung · Cancer of the Lung · Lung Cancer · Neoplasms, Lung · Neoplasms, Pulmonary · Pulmonary Cancer · Pulmonary Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 344 (final count)
- Started
- Feb 24, 2021
- Main results expected
- Jan 25, 2027
- Fully finished
- Jan 25, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of monotherapy or combination treatment
Measured over: 21 days
Dose Escalation: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: 24 months
Dose Escalation: Frequency of dose interruptions and reductions, by treatment
Measured over: 24 months
Dose Escalation: Dose intensity by treatment
Measured over: 24 months
Dose Expansion: Overall response rate (ORR) per RECIST v1.1, by treatment
Measured over: 24 months
Dose expansion: Overall intracranial response rate (OIRR) per mRANO-BM
Measured over: 24 months
Dose expansion: Incidence and severity of AEs and SAEs
Measured over: 24 months
Dose expansion: frequency of dose interruptions and reductions, by treatment
Measured over: 24 months
Dose expansion: Dose intensity by treatment
Measured over: 24 months
Dose expansion: ORR per RECIST 1.1 of JDQ443 single agent in patients with non-small cell lung cancer (JDQ443 dose randomization group only)
Measured over: 24 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04699188 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC